Q3 Earnings Forecast for NAMS Issued By HC Wainwright

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) – Analysts at HC Wainwright issued their Q3 2026 EPS estimates for NewAmsterdam Pharma in a research report issued on Thursday, February 19th. HC Wainwright analyst L. Egana-Gorrono forecasts that the company will earn ($0.59) per share for the quarter. HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.75) per share.

Several other research firms also recently issued reports on NAMS. Royal Bank Of Canada increased their target price on NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Thursday, January 22nd. Stifel Nicolaus raised their target price on NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Needham & Company LLC lifted their target price on NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.00.

NewAmsterdam Pharma Trading Down 3.2%

Shares of NAMS stock opened at $34.63 on Friday. The firm’s 50 day moving average is $34.00 and its 200 day moving average is $32.45. The stock has a market capitalization of $3.93 billion, a P/E ratio of -20.02 and a beta of 0.06. NewAmsterdam Pharma has a 12 month low of $14.06 and a 12 month high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative return on equity of 25.99% and a negative net margin of 906.22%.The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.92 million.

Insider Transactions at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 32,612 shares of the firm’s stock in a transaction that occurred on Wednesday, January 28th. The shares were sold at an average price of $31.80, for a total value of $1,037,061.60. Following the sale, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at $774,425.40. This trade represents a 57.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Johannes Jacob Piete Kastelein sold 6,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $33.25, for a total transaction of $199,500.00. Following the sale, the insider owned 73,481 shares of the company’s stock, valued at approximately $2,443,243.25. The trade was a 7.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 298,647 shares of company stock valued at $10,236,050. Corporate insiders own 20.84% of the company’s stock.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of institutional investors have recently made changes to their positions in the stock. Jennison Associates LLC boosted its position in NewAmsterdam Pharma by 42.5% during the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock valued at $119,407,000 after buying an additional 1,252,451 shares during the period. Atle Fund Management AB increased its holdings in shares of NewAmsterdam Pharma by 23.2% in the third quarter. Atle Fund Management AB now owns 193,625 shares of the company’s stock worth $5,507,000 after buying an additional 36,402 shares during the period. Keybank National Association OH bought a new stake in shares of NewAmsterdam Pharma in the 3rd quarter valued at about $455,000. Franklin Resources Inc. boosted its holdings in NewAmsterdam Pharma by 30.6% during the 2nd quarter. Franklin Resources Inc. now owns 334,212 shares of the company’s stock valued at $6,053,000 after acquiring an additional 78,300 shares during the period. Finally, Frazier Life Sciences Management L.P. grew its position in NewAmsterdam Pharma by 3.0% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company’s stock worth $300,754,000 after acquiring an additional 490,656 shares during the last quarter. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.